Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Gliknik Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT05318534
- Locations
- 🇬🇧
Fortrea Clinical Research Unit Ltd, Leeds, United Kingdom
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Gliknik Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02873819
- Locations
- 🇭🇺
Bacs-Kiskun County Teaching Hospital, Kecskemét, Hungary
🇭🇺Medical Center of the University of Pecs, Pecs, Hungary
🇺🇦Ivano-Frankivsk Regional Oncology Center, Ivano-Frankivsk, Ukraine
© Copyright 2024. All Rights Reserved by MedPath